title: Class I histone deacetylases 1, 2 and 3 are highly expressed in classical Hodgkin's lymphoma.
abstract: OBJECTIVE
  HDAC inhibitors (HDI) are anti-neoplastic drugs with preliminary successful clinical applications in Hodgkin's lymphoma (HL). Systematic investigations of HDAC expression in HL, based on histology and immunohistochemistry are yet rare.
  
  
  METHODS
  We investigated the expression of HDAC1, 2 and 3 in 283 HL on tissue microarrays.
  
  
  METHODS
  Expression of HDAC isoforms was scored in Hodgkin and Reed-Sternberg cells (HRSC) and background infiltrate and compared with freedom of treatment failure (FTF) in 118 cases, for which all data was available.
  
  
  RESULTS
  All analyzable HL expressed the HDAC isoforms 2 (n = 194) and 3 (n = 207) in over 50%, mostly 100%, of HRSC and almost all background lymphocytes. HDAC1 was expressed in 169 of 179 analyzable HL in a mean of 82% and in 172 out of 179 analyzable cases in a mean of 83% of infiltrating lymphocytes. HDAC1 of below 75% in HRSC correlated with worse FTF with 16 out of 32 events, compared with 16 out of 82 in cases with over 75% HDAC1-expressing HRSC.
  
  
  CONCLUSIONS
  HDAC isoforms 1, 2 and 3 are highly expressed in HL. In addition, decreased HDAC1 expression is accompanied by worse outcome in HL.
authors.affiliation: Institute for Pathology, Zurich University Hospital, Schmelzbergstrasse 12, CH-8091 Zurich, Switzerland. heiner.adams@usz.ch
authors.forename: Heiner
authors.initials: H
authors.lastname: Adams
authors.forename: Florian R
authors.initials: FR
authors.lastname: Fritzsche
authors.forename: Stephan
authors.initials: S
authors.lastname: Dirnhofer
authors.forename: Glen
authors.initials: G
authors.lastname: Kristiansen
authors.forename: Alexandar
authors.initials: A
authors.lastname: Tzankov
mesh_terms: D000328:Adult; D005260:Female; D005500:Follow-Up Studies; D015972:Gene Expression Regulation, Neoplastic; D056284:Histone Deacetylase 1 / Q000235:genetics*; D056464:Histone Deacetylase 2 / Q000235:genetics*; D006655:Histone Deacetylases / Q000235:genetics*; D006689:Hodgkin Disease / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D006801:Humans; D008214:Lymphocytes / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D016539:Reed-Sternberg Cells / Q000378:metabolism; D046888:Tissue Array Analysis; D016896:Treatment Outcome; D000099186:Histone Deacetylase 3
chemical_list: D056284:Histone Deacetylase 1; D056464:Histone Deacetylase 2; D006655:Histone Deacetylases; D000099186:Histone Deacetylase 3